CDC December Vaccine Advisory Meeting Preview

CDC’s Vaccine Advisory Committee to Convene Amid Controversial Changes

The Centers for Disease Control and Prevention’s vaccine advisory committee is set to meet December 4-5 to discuss several critical vaccination issues, including potential changes to hepatitis B vaccination timing for newborns, the childhood vaccine schedule, and vaccine ingredients.

The Advisory Committee on Immunization Practices (ACIP), which was reconstituted in June by Health and Human Services Secretary Robert F. Kennedy Jr., has already drawn scrutiny for departing from its traditionally evidence-based approach. The committee nearly voted in September to delay the birth dose of hepatitis B vaccine, but ultimately tabled the decision without providing a clear scientific rationale.

Dr. Kirk Milhoan, recently appointed as the new ACIP chair, confirmed to the Washington Post that the group would vote on delaying the hepatitis B birth dose during this week’s meeting. Milhoan, a pediatric cardiologist and Kennedy appointee, has previously promoted treatments for COVID-19 not supported by scientific evidence and made unfounded claims about COVID-19 vaccination.

The potential delay of the hepatitis B birth dose has alarmed public health experts. Since universal infant hepatitis B vaccination was implemented in 1991, infections in children have plummeted by 99%. Medical experts emphasize that babies and young children infected with hepatitis B virus are particularly vulnerable to developing chronic infections that can lead to liver failure and liver cancer.

Kennedy has repeatedly claimed the birth dose is unnecessary because hepatitis B spreads through sexual contact and drug use. However, this overlooks that infected mothers can transmit the virus during childbirth, and babies can be exposed through minute amounts of blood from family members or close contacts. Approximately half of Americans with hepatitis B are unaware they’re infected, according to CDC data presented in September.

A December 2 review by the University of Minnesota’s Vaccine Integrity Project found “no evidence of any health benefit with delaying the birth dose and identified only risks related to changing current US recommendations for universal hepatitis B vaccination.”

Changes to the hepatitis B vaccination schedule could have far-reaching impacts beyond a single vaccine. Pharmaceutical company Sanofi warned in a public comment that altering recommendations “risk reducing options for families and could disrupt vaccine supply and limit access for years” because many vaccines are administered in combination formulations.

The second day of the meeting will address broader topics including vaccine safety, adjuvants, “contaminants,” and the overall vaccine schedule. While no votes are scheduled for these items, the discussions align with a new ACIP work group established under Kennedy to review “the safety and effectiveness” of childhood and adolescent vaccinations.

Milhoan indicated the committee will begin discussing aluminum adjuvants, substances added to vaccines in small amounts to improve immune response. Kennedy has recently made misleading statements about aluminum adjuvants, incorrectly suggesting a link to autism based on selective interpretation of a Danish study. In reality, this comprehensive study found no association between aluminum in vaccines and 50 chronic conditions, including autism.

The committee’s shift in approach comes amid significant structural changes. In October, CDC staffers supporting the committee were reportedly dismissed. Meanwhile, at the FDA, a leaked November 28 letter from vaccines regulatory division head Dr. Vinay Prasad announced plans for stricter vaccine regulation, citing contested claims about COVID-19 vaccine safety.

Public health experts continue to stress that the childhood vaccine schedule has been built over decades based on multiple considerations, including optimal timing for protection, established safety of simultaneous immunizations, and practical implementation factors for healthcare providers and families.